Fluxion Biosciences Awarded NCI Grant For Development Of Rare Cell Isolation Platform

Main Category: Cancer / Oncology
Article Date: 23 Jul 2009 - 22:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life science research, announced that it has received a $200K grant from the National Cancer Institute (NCI) for the development of a rare cell isolation platform for diagnostic and research applications. The Phase One Small Business Innovation Research Grant will enable Fluxion to further develop its innovative microfluidic platform. The endpoints of this research include enhanced methods for detecting circulating tumor cells that appear in very low concentrations in the early stages of cancer.

Circulating tumor cells (CTCs) are cells that detach from a primary tumor and circulate throughout the bloodstream. These cells are part of the metastasizing process that leads to the progression of the disease. It is widely believed that the detection of CTCs in the blood is an important factor in monitoring an individual's baseline condition and ongoing response to therapy. Despite the high value of this information, these tests are rarely performed due to the difficulty in tracking CTCs, which can appear in as little as one in one billion blood cells. This newly awarded grant is focused on the development of a microfluidic system that enhances the detection ability of CTCs as well as other rare cell types. The principal aims of this grant include the design of novel microfluidic systems for magnetic-bead based cell separations and the associated control instrumentation.

"We are excited to receive this NCI grant for this compelling application of our microfluidic technology," said Carolyn Conant, Ph.D., project leader for the grant. "The ability to detect and isolate rare cells can have a profound impact in the fields of oncology, immunology and neonatal care."

Source
Fluxion Biosciences

Article adapted by Medical News Today from original press release.
Visit our cancer / oncology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Fluxion Biosciences. "Fluxion Biosciences Awarded NCI Grant For Development Of Rare Cell Isolation Platform." Medical News Today. MediLexicon, Intl., 23 Jul. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/158588.php>

APA
Fluxion Biosciences. (2009, July 23). "Fluxion Biosciences Awarded NCI Grant For Development Of Rare Cell Isolation Platform." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/158588.php.

Please note: If no author information is provided, the source is cited instead.


Cancer / Oncology

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Read more...

Most Popular Articles



Follow Our Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cancer / Oncology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »